Guaifenesin-Ketamine-Xylazine Infusions to Provide Anesthesia in Donkeys

The purpose of this study was to determine a satisfactory combination of guaifenesin, ketamine, and xylazine (GKX) that would produce safe and satisfactory total intravenous anesthesia in donkeys for use under field conditions. Donkeys require higher amounts of ketamine in GKX to achieve satisfactory anesthetic levels without producing excessive depression with guaifenesin. Five adult standard donkeys (average weight, 264 kg) were anesthetized with 1.5 mg/mL ketamine, 0.5 mg/mL xylazine, 50 mg/mL guaifenesin (GKX-1); 2.0 mg/mL ketamine, 0.5 mg/mL xylazine, 50 mg/mL guaifenesin (GKX-2); or 2.0 mg/mL ketamine, 0.75 mg/mL xylazine, 50 mg/mL guaifenesin (GKX-3). For the first trial, two donkeys received GKX-1, two received GKX-2, and one received GKX-3. One donkey received GKX-1, one received GKX-2, and three received GKX-3 for the second trial. In the final trial, two received GKX-1, two received GKX-2, and one received GKX-3. Donkeys were sedated with xylazine (1.1 mg/kg body weight) intravenously, and anesthesia was induced using intravenous GKX-1, GKX-2, or GKX-3. Anesthesia was maintained for 45 minutes; temperature, respiration rate, heart rate, hemoglobin saturation, partial pressure of arterial oxygen (PaO₂), partial pressure of carbon dioxide in arterial gas (PaCO₂), and pH were measured. There was no significant difference between combinations for temperature, respiration rate, heart rate, hemoglobin saturation, PaCO₂, or pH. At 30 and 45 minutes, GKX-3 produced significantly (P < .05) lower PaO₂ values than GKX-1 and GKX-2. GKX-3 is not recommended for field use in donkeys because of respiratory depression (PaO₂= 48.7 [±5.84] and 46.0 ± 3.11 mmHg at 30 and 45 minutes, respectively), whereas more voluntary movement was apparent with GKX-1. GKX-2 produced satisfactory anesthesia without significant respiratory depression in donkeys and should produce safe and effective anesthesia in donkeys under field conditions.     

静脉注射不同形态锰源对肉仔鸡生物学活性的影响

【目的】研究经静脉注射途径进入体内的不同形态锰在肉仔鸡体内代谢利用上的差异。【方法】将180只22日龄肉公鸡按体重随机分为5个处理组,分别翅静脉注射生理盐水,或在生理盐水中溶解硫酸锰及弱、中等和强络合强度有机锰源的注射液20 d。【结果】静脉注射后第10和20天,各注射锰源组鸡的跖骨灰锰含量、心肌锰含量、心肌细胞线粒体中MnSOD活性和MnSOD mRNA均显著（P＜0.03）高于注射生理盐水的对照组,但前3项指标未能恒定一致地反映出不同形态锰对肉仔鸡的生物学活性的差异。注射中等络合强度锰源组心肌细胞线粒体中MnSOD mRNA水平显著高于注射硫酸锰组（P＜0.01）和强络合强度锰源组（P＜0.09）,且注射弱络合强度锰源组心肌细胞线粒体中MnSOD mRNA水平显著高于注射硫酸锰组（P＜0.06）。【结论】注射锰在转录水平上显著影响心肌细胞线粒体中MnSOD的基因表达, 这一功能性基因表达指标比其酶活性等其它指标更敏感、更恒定地监测出肉仔鸡对不同锰间生物学利用性的差异。经静脉注射途径进入体内的中等和弱络合强度有机锰源对肉仔鸡的生物学活性显著高于无机锰,而强络合强度有机锰源不利于肉仔鸡体组织细胞对其中锰的利用。     

Retrospective evaluation of parenteral nutrition in alpacas: 22 cases (2002-2008)

Background: Parenteral nutrition is an important method of nutritional support in hospitalized animals, but minimal information has been published on its use in camelids. Hypothesis/Objectives: The purpose of this study was to characterize the use of total parenteral nutrition (TPN) in alpacas, evaluate the formulations used, and determine potential complications. Animals: Twenty‐two alpacas hospitalized at the Tufts Cummings School for Veterinary Medicine (site 1: n = 8) and the Ohio State University Veterinary Teaching Hospital (site 2: n = 14). Methods: A retrospective analysis of all alpacas that received TPN between 2002 and 2008 was performed to assess clinical indications, clinical and clinicopathologic data, and outcome. Results: The most common underlying diseases in animals receiving TPN were gastrointestinal dysfunction (n = 16), hepatic disease (n = 2), and neoplasia (n = 2). Several metabolic abnormalities were identified in animals (n = 20/22) before TPN was initiated, including lipemia (n = 12/22), hyperglycemia (11/22), and hypokalemia (n = 11/22). Median age was significantly lower for site 1 cases (0.1 years; range, 0.01–11.0) compared with those from site 2 (4.9 years; range, 0.1–13.7; P= .03). Animals at site 2 also had a longer duration of hospitalization (P= .01) and TPN administration (P= .004), as well as higher survival rate (P < .02). Twenty‐one of 22 alpacas developed at least 1 complication during TPN administration. Metabolic complications were most prevalent (n = 21/22) and included hyperglycemia (n = 8/21), lipemia (n = 7/21), hypokalemia (n = 3/21), and refeeding syndrome (n = 3/21). Conclusions and Clinical Importance: TPN is a feasible method of nutritional support for alpacas when enteral feeding is not possible. Prospective studies are warranted to determine optimal TPN formulations for alpacas.     

Clinical and pharmacokinetic evaluation of S-ketamine for intravenous general anaesthesia in horses undergoing field castration

Background

Intravenous anaesthetic drugs are the primary means for producing general anaesthesia in equine practice. The ideal drug for intravenous anaesthesia has high reliability and pharmacokinetic properties indicating short elimination and lack of accumulation when administered for prolonged periods. Induction of general anaesthesia with racemic ketamine preceded by profound sedation has already an established place in the equine field anaesthesia. Due to potential advantages over racemic ketamine, S-ketamine has been employed in horses to induce general anaesthesia, but its optimal dose remains under investigation. The objective of this study was to evaluate whether 2.5 mg/kg S-ketamine could be used as a single intravenous bolus to provide short-term surgical anaesthesia in colts undergoing surgical castration, and to report its pharmacokinetic profile.

Results

After premedication with romifidine and L-methadone, the combination of S-ketamine and diazepam allowed reaching surgical anaesthesia in the 28 colts. Induction of anaesthesia as well as recovery were good to excellent in the majority (n = 22 and 24, respectively) of the colts. Seven horses required additional administration of S-ketamine to prolong the duration of surgical anaesthesia. Redosing did not compromise recovery quality. Plasma concentration of S-ketamine decreased rapidly after administration, following a two-compartmental model, leading to the hypothesis of a consistent unchanged elimination of the parent compound into the urine beside its conversion to S-norketamine. The observed plasma concentrations of S-ketamine at the time of first movement were various and did not support the definition of a clear cut-off value to predict the termination of the drug effect.

Conclusions

The administration of 2.5 mg/kg IV S-ketamine after adequate premedication provided good quality of induction and recovery and a duration of action similar to what has been reported for racemic ketamine at the dose of 2.2 mg/kg. Until further investigations will be provided, close monitoring to adapt drug delivery is mandatory, particularly once the first 10 minutes after injection are elapsed. Taking into account rapid elimination of S-ketamine, significant inter-individual variability and rapid loss of effect over a narrow range of concentrations a sudden return of consciousness has to be foreseen.     

Pharmacokinetics of doxycycline in sheep after intravenous and oral administration

The pharmacokinetics of doxycycline were investigated in sheep after oral (PO) and intravenous (IV) administration. The IV data were best described using a 2- (n = 5) or 3- (n = 6) compartmental open model. Mean pharmacokinetic parameters obtained using a 2-compartmental model included a volume of distribution at steady-state (V_ss) of 1.759 ± 0.3149 L/kg, a total clearance (Cl) of 3.045 ± 0.5264 mL/kg/min and an elimination half-life (t_1/2β) of 7.027 ± 1.128 h. Comparative values obtained from the 3-compartmental mean values were: V_ss of 1.801 ± 0.3429 L/kg, a Cl of 2.634 ± 0.6376 mL/kg/min and a t_1/2β of 12.11 ± 2.060 h. Mean residence time (MRT_0−∞) was 11.18 ± 3.152 h. After PO administration, the data were best described by a 2-compartment open model. The pharmacokinetic parameter mean values were: maximum plasma concentration (C_max), 2.130 ± 0.950 μg/mL; time to reach C_max (t_max), 3.595 ± 3.348 h, and absorption half-life (t_1/2k01), 36.28 ± 14.57 h. Non-compartmental parameter values were: C_max, 2.182 ± 0.9117 μg/mL; t_max, 3.432 ± 3.307 h; F, 35.77 ± 10.20%, and mean absorption time (MAT_0–∞), 25.55 ± 15.27 h. These results suggest that PO administration of doxycycline could be useful as an antimicrobial drug in sheep.